A triple agonist activates three (retatrutide: GIP + GLP-1 + glucagon) [1][5]
These considerations can significantly impact your ability to start and continue treatment
GLP-1 & Muscle Loss: Evidence and Prevention GLP-1 receptor agonists such as semaglutide and liraglutide have transformed weight management for people with obesity, but concerns about muscle loss during treatment are increasingly common
Dopamine replacement therapies do not alter the underlying disease course, and over-reliance on escalating doses can lead to complications, such as motor fluctuations, dyskinesias, and other side effects, ultimately diminishing the patients quality of life 18
PMCID: PMC10698219
The internal solution for the inside-out recordings matched that used for the whole-cell and cell-attached methods, whereas the external solution (intracellular side) differed slightly, containing 2 mM CaCl 2 instead of EGTA